Do analysts recommend LYRA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PFSA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PFSA or VERO more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer SSKN or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DYNT or VERO?

Given Dynatronics' higher probable upside, equities analysts clearly believe Dynatronics is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DYNT or VERO more profitable?

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Dynatronics -8.35% -41.81% -9.56% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts recommend BIOL or VERO?

Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or VERO more profitable?

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Venus Concept -92.76% -1,904.25% -85.22%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 06/11/2026

Compare

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

Should you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include Lyra Therapeutics (LYRA), Profusa (PFSA), Strata Skin Sciences (SSKN), Dynatronics (DYNT), and BIOLASE (BIOL). These companies are all part of the "medical equipment" industry.

How does Venus Concept compare to Lyra Therapeutics?

Lyra Therapeutics (NASDAQ:LYRA) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.63	-$93.43M	-$19.15	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Lyra Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Venus Concept	Neutral

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lyra Therapeutics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Profusa?

Profusa (NASDAQ:PFSA) and Venus Concept (NASDAQ:VERO) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

9.8% of Profusa shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 0.8% of Profusa shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	10.45	-$35.82M	-$169.72	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Profusa had 4 more articles in the media than Venus Concept. MarketBeat recorded 4 mentions for Profusa and 0 mentions for Venus Concept. Profusa's average media sentiment score of 0.66 beat Venus Concept's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Overall Sentiment
Profusa	Positive
Venus Concept	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Profusa beats Venus Concept on 8 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Strata Skin Sciences?

Strata Skin Sciences (NASDAQ:SSKN) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

In the previous week, Strata Skin Sciences had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Strata Skin Sciences and 0 mentions for Venus Concept. Strata Skin Sciences' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Strata Skin Sciences	Neutral
Venus Concept	Neutral

32.4% of Strata Skin Sciences shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 40.9% of Strata Skin Sciences shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Strata Skin Sciences has higher earnings, but lower revenue than Venus Concept. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Skin Sciences	$30.98M	0.02	-$10.09M	-$1.41	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Strata Skin Sciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Strata Skin Sciences has a net margin of -35.64% compared to Venus Concept's net margin of -92.76%. Strata Skin Sciences' return on equity of -476.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Skin Sciences	-35.64%	-476.73%	-33.49%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Strata Skin Sciences beats Venus Concept on 8 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Venus Concept	-92.76%	-1,904.25%	-85.22%

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dynatronics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Dynatronics has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Dynatronics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Dynatronics	Neutral
Venus Concept	Neutral

Given Dynatronics' higher probable upside, equities analysts clearly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dynatronics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Venus Concept	-92.76%	-1,904.25%	-85.22%

BIOLASE has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Venus Concept	Neutral

Summary

BIOLASE beats Venus Concept on 8 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$442K	$7.21B	$6.75B	$12.02B
Dividend Yield	N/A	1.21%	2.66%	5.61%
P/E Ratio	-0.01	47.89	24.04	24.43
Price / Sales	0.01	71.27	510.75	109.73
Price / Cash	N/A	25.17	44.01	55.64
Price / Book	0.07	6.89	10.66	6.79
Net Income	-$47M	$159.22M	$3.56B	$337.66M
7 Day Performance	N/A	-1.36%	0.05%	2.08%
1 Month Performance	N/A	3.84%	0.37%	3.16%
1 Year Performance	-87.87%	-0.34%	22.73%	27.78%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
LYRA Lyra Therapeutics	0.2067 of 5 stars	$0.80 +14.3%	N/A	-94.8%	$1.42M	$600K	N/A	50	Gap Down
PFSA Profusa	0.2624 of 5 stars	$0.28 -6.6%	N/A	N/A	$1.37M	$100K	N/A	2	News Coverage Positive News Gap Down
SSKN Strata Skin Sciences	0.1093 of 5 stars	$0.12 -7.6%	N/A	-94.3%	$712K	$30.98M	N/A	120
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

How does Venus Concept compare to Lyra Therapeutics?

Summary

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to BIOLASE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

How does Venus Concept compare to Lyra Therapeutics?

Do analysts recommend LYRA or VERO?

Is LYRA or VERO more profitable?

Which has better earnings & valuation, LYRA or VERO?

Which has more volatility & risk, LYRA or VERO?

Does the media refer more to LYRA or VERO?

Do institutionals and insiders believe in LYRA or VERO?

Summary

How does Venus Concept compare to Profusa?

Which has more volatility and risk, PFSA or VERO?

Do insiders & institutionals hold more shares of PFSA or VERO?

Is PFSA or VERO more profitable?

Which has stronger earnings & valuation, PFSA or VERO?

Does the media favor PFSA or VERO?

Do analysts recommend PFSA or VERO?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Does the media favor SSKN or VERO?

Do insiders and institutionals have more ownership in SSKN or VERO?

Which has better earnings and valuation, SSKN or VERO?

Which has more risk & volatility, SSKN or VERO?

Do analysts prefer SSKN or VERO?

Is SSKN or VERO more profitable?

Summary

How does Venus Concept compare to Dynatronics?

Is DYNT or VERO more profitable?

Do insiders & institutionals believe in DYNT or VERO?

Which has more volatility & risk, DYNT or VERO?

Which has better earnings & valuation, DYNT or VERO?

Does the media prefer DYNT or VERO?

Do analysts recommend DYNT or VERO?

Summary

How does Venus Concept compare to BIOLASE?

Do analysts recommend BIOL or VERO?

Which has more volatility & risk, BIOL or VERO?

Is BIOL or VERO more profitable?

Which has higher earnings & valuation, BIOL or VERO?

Do insiders & institutionals hold more shares of BIOL or VERO?

Does the media prefer BIOL or VERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools